Today: 21 May 2026
Browse Category

NASDAQ:SLXN 21 May 2026

Stock Market Today

  • S&P 500 Futures Slide as Investors Digest Nvidia Earnings and Intuit Workforce Cuts
    May 20, 2026, 6:30 PM EDT. S&P 500 futures slipped 0.3% following mixed earnings reports, with Nvidia's revenue rising 85% year-over-year to $81.62 billion, beating estimates but shares falling 1.4% amid high growth expectations. Intuit shares dropped over 10% after missing revenue forecasts and announcing a 17% workforce reduction. E.l.f. Beauty shares climbed nearly 5% after exceeding sales and earnings expectations and reversing tariff-driven price hikes. The market rebounded Wednesday, ending a three-day slump as oil prices and bond yields eased. Investors await Walmart and Workday earnings ahead of economic data on jobless claims, housing, and manufacturing. Persistent inflation and demand worries contrast with positive earnings revisions, reflecting cautious sentiment in U.S. equity markets.

Latest articles

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

21 May 2026
AEVEX Corp. shares surged over 10% after hours Wednesday following a first-quarter profit of $21 million and new U.S. Air Force contracts worth $15.6 million. Revenue jumped to $216.7 million, beating estimates. The company, which went public in April, raised its full-year revenue outlook to $600–$620 million. The stock had closed regular trading at $26.27, down 0.23%.
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

21 May 2026
Jupiter Neurosciences shares fell 37% to $0.205 Wednesday after announcing a proposed U.S. licensing deal for PharmAla Biotech’s MDMA-based ALA-002 and a $2 million stock offering. Trading volume topped 230 million shares. The licensing agreement is non-binding, with a potential value over $100 million, and gives Jupiter 90 days to finalize terms. Jupiter reported a $2.06 million Q1 net loss and $2.36 million in cash.
Go toTop